Pfizer (PFE) Intangibles (2009 - 2026)
Pfizer (PFE) posted quarterly Intangibles of $52.6 billion for Q1 2026, down 2.63% year-over-year from $54.0 billion in Q1 2025, and down 2.18% quarter-over-quarter from $53.7 billion in Q4 2025.
Pfizer (PFE) Intangibles (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Intangibles for 18 consecutive years, with $52.6 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Intangibles fell 2.63% year-over-year to $52.6 billion; the TTM figure through Mar 2026 stood at $52.6 billion (down 2.63% YoY), while the FY2025 annual figure was $53.7 billion, down 3.03% from the prior year.
- Intangibles eased to $52.6 billion in Q1 2026 per PFE's latest filing, from $53.7 billion in the prior quarter.
- Across five years, Intangibles topped out at $64.9 billion in Q4 2023 and bottomed at $29.1 billion in Q3 2022.
- Historically, Intangibles has averaged $50.3 billion across 5 years, with a median of $52.7 billion in 2025.
- Annual changes were most pronounced in 2022 — Intangibles jumped 72.47% — and 2024, when it declined 14.62%.
- Pfizer's Intangibles stood at $43.4 billion in 2022, then surged by 49.64% to $64.9 billion in 2023, then dropped by 14.62% to $55.4 billion in 2024, then decreased by 3.03% to $53.7 billion in 2025, then retreated by 2.18% to $52.6 billion in 2026.
- Business Quant data shows PFE's Intangibles at $52.6 billion in Q1 2026, $53.7 billion in Q4 2025, and $51.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.29 Bn | 631.53 Bn | 17.26 Bn | 48.23 Bn |
| 2 | AbbVie | 470.62 Bn | 464.06 Bn | 12.70 Bn | 49.14 Bn |
| 3 | Merck | 375.66 Bn | 368.52 Bn | 12.21 Bn | 24.98 Bn |
| 4 | Novartis Ag | 302.90 Bn | 295.21 Bn | 11.24 Bn | 42.07 Bn |
| 5 | Astrazeneca | 257.50 Bn | 252.60 Bn | 12.86 Bn | 37.72 Bn |
| 6 | Amgen | 237.19 Bn | 223.20 Bn | 7.24 Bn | 20.49 Bn |
| 7 | Gilead Sciences | 182.92 Bn | 179.74 Bn | 6.22 Bn | 14.03 Bn |
| 8 | Pfizer | 160.14 Bn | 148.44 Bn | 10.94 Bn | 47.05 Bn |
| 9 | Gsk | 106.08 Bn | 101.91 Bn | 8.24 Bn | 22.54 Bn |
| 10 | Sanofi | 55.22 Bn | 47.84 Bn | 10.79 Bn | 30.64 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 47.05 Bn |
| Mar 29, 2026 | 52.56 Bn |
| Dec 31, 2025 | 53.73 Bn |
| Sep 28, 2025 | 51.32 Bn |
| Jun 29, 2025 | 52.70 Bn |
| Mar 30, 2025 | 53.98 Bn |
| Dec 31, 2024 | 55.41 Bn |
| Sep 29, 2024 | 59.99 Bn |
| Jun 30, 2024 | 61.24 Bn |
| Mar 31, 2024 | 62.83 Bn |
| Dec 31, 2023 | 64.90 Bn |
| Jul 2, 2023 | 41.41 Bn |
| Apr 2, 2023 | 42.00 Bn |
| Dec 31, 2022 | 43.37 Bn |
| Jul 3, 2022 | 29.07 Bn |
| Apr 3, 2022 | 29.82 Bn |
| Dec 31, 2021 | 25.15 Bn |
| Oct 3, 2021 | 26.31 Bn |
| Jul 4, 2021 | 27.32 Bn |
| Apr 4, 2021 | 27.97 Bn |